Probucol in Alzheimer’s Study/PIA Study

Back to Drug Development Trials
Drug Development Trials

About the trial

The Study aims to determine whether Probucol is effective for slowing the decline in memory and thinking skills in people with MCI (mild cognitive impairment) or mild Alzheimer’s disease, as well as the impact of Probucol on amyloid protein. Probucol is an anti-hyperlipidemic drug initially developed for the treatment of cardiovascular disease. Recent research has shown that Probucol appears to decrease microscopic blood vessel inflammation and reduce exposure to potentially toxic proteins in the brain. These microscopic blood vessels are important for maintaining brain function, cognition, and memory.

Who can be involved:

  • Male or female, aged 18-85 years, at the time of informed consent
  • Must be diagnosed with mild-moderate cognitive impairment due to probable Alzheimer’s disease or mild Alzheimer’s disease
  • Have an identified, reliable, study partner
  • If using medications to treat symptoms related to Alzheimer’s disease, doses must be stable for at least 3 months before screening

What is involved:

  • Weekly visits for five weeks, then approximately every three months
  • 2 years trial duration
  • Daily medication twice a day (oral tablet)
  • A positive amyloid result on a PET scan

Additional info:

For further information please contact the Clinical Trial Coordinator on Ph: 0468 532 458 or Email: piastudy@curtin.edu.au

*Please note that participants in this study may have a chance of being placed on a placebo medication.